Research and Markets: The Global Market for New Cancer Patients is Set to Increase from 4.0 Million Cases in the Major Can

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/b27603/cancer_market_tren) has announced the addition of the "Cancer Market Trends 2008 - 2012: Key Market Forecasts and Growth Opportunities (Update)" report to their offering.

Roche, Genentech and Merck tipped for strong growth in cancer markets says report

Just three of 2007's top companies producing cancer medicines are forecast to significantly grow their sales in the oncology segment over the next five years, says a new research report.

Commenting on the findings, Steve Seget, author of the report, said: "Roche is forecast to overtake Amgen to become the leading company by cancer sales in 2012." Other changes will include Genentech passing Novartis to become the third leading cancer company, while Merck will overtake Eli Lilly, Pfizer, AstraZeneca and Sanofi-Aventis to become the sixth leading cancer company in 2012.

Only five of the top 10 cancer products in 2007 are forecast to increase sales over the next five years, notes the report. Amgen's Aranesp and Epogen, J&J's Eprex/Procrit and Sanofi-Aventis' Taxotere and Eloxatin are all forecast to suffer declining sales between 2007 and 2012.

The 120 page report forecasts that the global market for pharmaceutical cancer treatments will grow to $103.9 billion by 2012, equivalent to a CAGR of 9.4% over the next five years. The global market for new cancer patients is set to increase from 4 million cases in the major pharmaceutical markets in 2007 to 4.2 million in 2012.

The global cancer market has seen a continued period of rapid growth. Global sales for cancer-treating drugs increased by 13.3% in 2007, primarily driven by growth in sales of innovative drugs. Although growth rates for this market will slow due to generic competition, the market is predicted to expand to $103.9 billion by 2012, equivalent to CAGR of 9.4%.

Companies Mentioned:

  • Amgen
  • AstraZeneca
  • Eli Lilly
  • Genentech
  • Johnson & Johnson
  • Merck
  • Novartis
  • Pfizer
  • Roche
  • Sanofi-Aventis

For more information visit http://www.researchandmarkets.com/research/b27603/cancer_market_tren

Source: Spectra Intelligence



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   Europe  Ireland

INDUSTRY KEYWORDS:   Health  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Monday, Bernstein analysts echoed what many were probably thinking about Novo Nordisk’s Rybselsus price: “Finally we can stop talking about it.”

Low interest rates and strong stock valuations are two top reasons why U.S. drugmakers are on the move for deals.

Despite a 45% premium offered to Allergan investors through the AbbVie buyout, one investor is suing to block the deal.